Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

(2020) Nahomi Tokudome et al.   BMC CANCER

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

(2020) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations

(2020) Chunhua Ma et al.   Frontiers in Oncology

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

(2020) Valerio Gristina et al.   CANCER TREATMENT REVIEWS

Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

(2020) Iosune Baraibar et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation

(2020) Takae Okuno et al.   LUNG CANCER

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

(2020) S. Park et al.   ANNALS OF ONCOLOGY

Understanding EGFR heterogeneity in lung cancer

(2020) Antonio Passaro et al.   ESMO Open

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

(2019) Alessandro Russo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations

(2019) Jenn-Yu Wu et al.   Clinical Lung Cancer

Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations

(2019) Sheng-Kai Liang et al.   LUNG CANCER

Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment

(2019) Tianli Zhang et al.   Translational Lung Cancer Research

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer

(2019) Vanita Noronha et al.   JOURNAL OF CLINICAL ONCOLOGY

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib

(2019) Ashiq Masood et al.   SEMINARS IN ONCOLOGY

Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study

(2019) Yukio Hosomi et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generations

(2019) Riyaz Shah et al.   Clinical Lung Cancer

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

(2019) Jang Ho Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

(2018) Sara Pilotto et al.   Clinical Lung Cancer

Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?

(2018) Nicolas Girard   Future Oncology

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review

(2018) Bao-Dong Qin et al.   OncoTargets and Therapy

Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations

(2018) Antonio Passaro et al.   Clinical Lung Cancer

Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing

(2018) Shinji Kohsaka et al.   Future Oncology

Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review

(2017) Adrian G. Sacher et al.   Journal of Thoracic Oncology

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations

(2017) Yi-Cheng Shen et al.   LUNG CANCER

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

(2017) Hai-Yan Tu et al.   LUNG CANCER

Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits

(2017) Wanlong Ma et al.   Molecular Diagnosis & Therapy

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer

(2017) Shinji Kohsaka et al.   Science Translational Medicine

Ascending Aorta Diameters: Normal, Abnormal, or Pathologic?

(2016) Hans-H. Sievers et al.   ANNALS OF THORACIC SURGERY

CompoundEGFRmutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma

(2016) Eun Young Kim et al.   CANCER BIOLOGY & THERAPY

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

(2016) Yoshihisa Kobayashi et al.   CANCER SCIENCE

First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

(2016) Martin Schuler et al.   Journal of Thoracic Oncology

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

(2016) Keunchil Park et al.   LANCET ONCOLOGY

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

(2016) Jianlin Xu et al.   LUNG CANCER

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer

(2016) Jenn-Yu Wu et al.   OncoTargets and Therapy

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

(2015) Jarushka Naidoo et al.   CANCER

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

(2015) Chao-Hua Chiu et al.   Journal of Thoracic Oncology

Efficacy of the Irreversible ErbB Family Blocker Afatinib in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)–Pretreated Non–Small-Cell Lung Cancer Patients with Brain Metastases or Leptomeningeal Disease

(2015) Petra Hoffknecht et al.   Journal of Thoracic Oncology

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

(2015) James C-H Yang et al.   LANCET ONCOLOGY

Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea

(2015) Jin Ho Baek et al.   LUNG CANCER

EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis

(2015) Chao Cheng et al.   Scientific Reports

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

(2014) Satoshi Watanabe et al.   Journal of Thoracic Oncology

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

(2014) Yi-Long Wu et al.   LANCET ONCOLOGY

Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations

(2014) Liang Peng et al.   Scientific Reports

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

(2013) M. Beau-Faller et al.   ANNALS OF ONCOLOGY

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

(2013) Bhumsuk Keam et al.   International Journal of Clinical Oncology

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

(2012) Susumu Kobayashi et al.   Journal of Thoracic Oncology

Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer

(2011) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations

(2009) I. Y.-S. Tam et al.   MOLECULAR CANCER THERAPEUTICS